Proportion of responders (at least 50% seizure frequency reduction in myoclonic seizures) · people with juvenile myoclonic epilepsy
It is very uncertain whether topiramate changes proportion of responders (at least 50% seizure frequency reduction… compared with valproate (very low certainty).
1 finding from 1 review
Proportion of responders (at least 50% seizure frequency reduction in PGTCS) · people with juvenile myoclonic epilepsy
It is very uncertain whether topiramate changes proportion of responders (at least 50% seizure frequency reduction… compared with valproate (very low certainty).
1 finding from 1 review
Proportion of participants who experienced at least one AE and individual AEs · people with juvenile myoclonic epilepsy
1 finding from 1 review
Seizure freedom · people with juvenile myoclonic epilepsy
It is very uncertain whether topiramate changes number of participants who were seizure‐free compared with valproate (very low certainty).
1 finding from 1 review
50% or greater reduction in seizure frequency · people with drug‐resistant focal epilepsy
Topiramate leads to higher 50% or greater reduction in seizure frequency (ITT analysis) compared with placebo (high certainty).
1 finding from 1 review
Seizure freedom · people with drug‐resistant focal epilepsy
Topiramate probably leads to higher seizure freedom compared with placebo (moderate certainty).
1 finding from 1 review
Treatment withdrawal · people with drug‐resistant focal epilepsy
Topiramate leads to higher treatment withdrawal compared with placebo (high certainty).
1 finding from 1 review
Adverse events ‐ weight loss · people with drug‐resistant focal epilepsy
Topiramate may leads to higher adverse effects ‐ weight loss/decrease compared with placebo (low certainty).
1 finding from 1 review
Paraesthesia · people with drug‐resistant focal epilepsy
Topiramate probably leads to higher adverse effects ‐ paraesthesia compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effects ‐ 'thinking abnormally' · people with drug‐resistant focal epilepsy
Topiramate leads to higher adverse effects ‐ 'thinking abnormally' compared with placebo (high certainty).
1 finding from 1 review
Adverse effects ‐ difficulty with concentration/concentration impaired/concentration‐attention difficulties · people with drug‐resistant focal epilepsy
Topiramate probably leads to higher adverse effects ‐ difficulty with concentration/concentration… compared with placebo (moderate certainty).
1 finding from 1 review
Time to treatment failure (any reason related to treatment) All participants ‐ adjusted by seizure type Range of · adults and children with newly onset partial or generalised epilepsy
Topiramate showed no clear difference in time to treatment failure (any reason related to treatment) All… compared with carbamazepine (moderate certainty).
1 finding from 1 review
Time to treatment failure (any reason related to treatment) Subgroup: focal onset seizures Range of · adults and children with newly onset partial or generalised epilepsy
Topiramate probably leads to higher time to treatment failure (any reason related to treatment)Subgroup:… compared with carbamazepine (moderate certainty).
1 finding from 1 review
Time to treatment failure (any reason related to treatment) Subgroup: generalised onset tonic‐clonic seizures or unclassified epilepsy Range of · adults and children with newly onset partial or generalised epilepsy
Topiramate showed no clear difference in time to treatment failure (any reason related to treatment)… compared with carbamazepine (low certainty).
1 finding from 1 review
Time to first seizure (post‐randomisation) All participants Range of · adults and children with newly onset partial or generalised epilepsy
Topiramate showed no clear difference in time to first seizure after randomisation All participants Range of compared with carbamazepine (high certainty).
1 finding from 1 review
Time to first seizure (post‐randomisation) Subgroup: focal onset seizures Range of · adults and children with newly onset partial or generalised epilepsy
Topiramate showed no clear difference in time to first seizure after randomisation Subgroup: focal onset… compared with carbamazepine (high certainty).
1 finding from 1 review
Time to first seizure after randomisation Subgroup: generalised onset tonic‐clonic seizures or unclassified epilepsy Range of · adults and children with newly onset partial or generalised epilepsy
Topiramate showed no clear difference in time to first seizure after randomisation Subgroup: generalised… compared with carbamazepine (moderate certainty).
1 finding from 1 review
Time to 12‐month remission ‐ all participants Range of · adults and children with newly onset partial or generalised epilepsy
Topiramate leads to lower time to 12‐month remission of seizures All participants Range of compared with carbamazepine (high certainty).
1 finding from 1 review
Time to achieve 12‐month remission (seizure‐free period) Subgroup: focal onset seizures Range of · adults and children with newly onset partial or generalised epilepsy
Topiramate leads to lower time to 12‐month remission of seizures Subgroup: focal onset… compared with carbamazepine (high certainty).
1 finding from 1 review
Time to 12‐month remission of seizures Subgroup: generalised onset tonic‐clonic seizures or unclassified epilepsy Range of · adults and children with newly onset partial or generalised epilepsy
Topiramate showed no clear difference in time to 12‐month remission of seizures Subgroup: generalised onset… compared with carbamazepine (moderate certainty).
1 finding from 1 review